COLUMBUS, OH, DNA Nanobots, a leader in the design and delivery of DNA nanoparticles engineered for targeted therapeutics, it has closed its pre-seed funding round.
DNA Nanobots, a leader in the design and delivery of DNA nanoparticles engineered for targeted therapeutics, announced that it has closed its pre-seed funding round. The investment enables DNA Nanobots to launch its BioPharma Partner Program to streamline its end-to-end custom biopharma solutions from design to development for preclinical and animal studies for improved delivery of a wide range of therapeutics.
(c) by Massinvestor, Inc. For contact info, please check out our
about page.
